FCFrancis X. Campion

Francis X. Campion

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francis X. Campion has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Angela M. Leung

    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA

    1 shared publication
  • Craig C Earle

    1 shared publication
  • Craig C. Earle

    Outcome Sciences, Cambridge, MA; American Society of Clinical Oncology, Alexandria, VA; Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Oncology Hematology Care, Cincinnati, OH

    1 shared publication
  • Elizabeth N. Pearce

    Section of Endocrinology, Diabetes, and Nutrition, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

    1 shared publication
  • Jeffrey R. Garber

    Endocrine Division, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA

    1 shared publication
  • Leanne R Larson

    1 shared publication

Latest Publications

  • Advancing Performance Measurement in Oncology: Quality Oncology Practice Initiative Participation and Quality Outcomes

    by Francis X. Campion, Leanne R. Larson, Pamela J. Kadlubek, Craig C. Earle, Michael N. Neuss

    American Society of Clinical Oncology Quality Oncology Practice Initiative has grown to include 973 practices as of 2010. Practices demonstrated rates of end-of-life care and other measures of quality.


    • 1 May 2011
      • p. SP32-6

    Advancing performance measurement in oncology.

    by Francis X Campion, Leanne R Larson, Pamela J Kadlubek, Craig C Earle, Michael N Neuss

    The American healthcare system, including the cancer care system, is under pressure to improve patient outcomes and lower the cost of care. Government payers have articulated an interest in partnering with the private sector to create learning communities to measure quality and improve the value of healthcare. In 2006, the American Society of Clinical Oncology (ASCO) unveiled the Quality Oncology Practice Initiative (QOPI), which has become a key component of the measurement system to promote quality cancer care. QOPI is a physician-led, voluntary, practice-based, quality-improvement program, using performance measurement and benchmarking among oncology practices across the United States. Since its inception, ASCO's QOPI has grown steadily to include 973 practices as of November 2010. One key area that QOPI has addressed is end-of-life care. During the most recent data collection cycle in the fall of 2010, those practices completing multiple data collection cycles had better performance on care of pain compared with sites participating for the first time (62.61% vs 46.89%). Similarly, repeat QOPI participants demonstrated meaningfully better performance than their peers in the rate of documenting discussions of hospice and palliative care (62.42% vs 54.65%) and higher rates of hospice enrollment. QOPI demonstrates how a strong performance measurement program can lead to improved quality and value of care for patients.


  • Open Access

    Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review

    by Angela M Leung, Shalini Dave, Stephanie L Lee, Francis X Campion, Jeffrey R Garber, Elizabeth N Pearce

    To assess predictors of well-differentiated thyroid cancer (WDTC) persistence/recurrence. This was a retrospective chart review of thyroid carcinoma patients seen 1979-2007 in a Boston, Massachusetts-area multispecialty group. Of 1,025 patients, 431 met eligibility criteria. Cox proportional hazards models were used to assess predictors (gender, age, ethnicity, tumor size, surgical histology) of WDTC persistence/recurrence (elevated thyroglobulin levels with negative thyroglobulin-antibodies; or positive imaging). Local extension of disease and lymph node involvement could not be assessed. Mean age at initial surgery (n = 431, 74% women, 79% Caucasian) was 45.8 ± 13.5(SD) years. Mean tumor (papillary, 91%; follicular, 5%; Hurthle cell, 2%; ≥1 type, 2%) size was 2.5 ± 1.6(SD) cm. Most tumors were unifocal (57%) and ≥1 cm (89%). Over 2,600 person-years of follow-up, persistence/recurrence occurred in 52 patients (12%) 4.3 years (median; range 0.2-23.2 years) after surgery. Gender, ethnicity, tumor size, multifocality, and histology were not predictive of persistence/recurrence, while older age was predictive in some models. In WDTC patients treated by total and near total thyroidectomy and radioiodine and analyzed without consideration of local, locoregional, and distant extent of disease, neither size of tumor nor male gender contribute to disease persistence/recurrence. Age at diagnosis seems to have some positive prognostic value even if only patients older than 21 years at diagnosis are considered. Due to the rare occurrence of follicular (also oxyphilic) histotype, this conclusion refers mainly to patients with papillary thyroid cancer.